Trial Profile

An open label, drug-drug interaction study of INCB054828 with CYP3A4 inhibitor (itraconazole) or inducer (rifampin)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Itraconazole (Primary) ; Pemigatinib; Rifampicin
Indications Cancer; Solid tumours
Focus Pharmacokinetics
Acronyms CYP3A-mediated DDI study

Most Recent Events

19 Jul 2021 Results published in the European Journal of Clinical Pharmacology
08 May 2019 New trial record
16 Mar 2019 Results presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com